Skip to content
All Podcasts – Lifestyle
Author:
HANCHORBIO INC.
HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy
October 5, 2026
HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit
September 9, 2026
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
July 8, 2026
HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions
May 28, 2026
HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
May 26, 2026
HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
April 24, 2026